TCGA-DK-A2HX-01A-12R-A18C-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 46.64914586
- os_event
- true
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.550
- PROTEIN_SECRETION+0.470
- UV_RESPONSE_DN+0.460
- APICAL_JUNCTION+0.370
- APICAL_SURFACE+0.350
- MYOGENESIS+0.330
- TGF_BETA_SIGNALING+0.330
- ESTROGEN_RESPONSE_EARLY+0.290
- NOTCH_SIGNALING+0.290
- ANGIOGENESIS+0.260
Top 10 suppressed
- MYC_TARGETS_V2-0.660
- MYC_TARGETS_V1-0.460
- E2F_TARGETS-0.430
- G2M_CHECKPOINT-0.360
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.320
- OXIDATIVE_PHOSPHORYLATION-0.290
- KRAS_SIGNALING_DN-0.270
- SPERMATOGENESIS-0.270
- FATTY_ACID_METABOLISM-0.220
- MTORC1_SIGNALING-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-64-1679-01A-21R-2066-07 | — | cohortA1 | 0.852 |
| 2 | TCGA-EW-A1PF-01A-11R-A144-07 | — | A | 0.846 |
| 3 | 20030015.LumB | — | A | 0.842 |
| 4 | TCGA-D8-A146-01A-31R-A115-07 | — | A | 0.841 |
| 5 | TCGA-FD-A5BZ-01A-11R-A28M-07 | — | — | 0.841 |
| 6 | TCGA-86-6562-01A-11R-1755-07 | — | cohortA1 | 0.840 |
| 7 | TCGA-A1-A0SH-01A-11R-A084-07 | — | A | 0.836 |
| 8 | TCGA-CV-5970-01A-11R-1686-07 | — | — | 0.828 |
| 9 | TCGA-CQ-7069-01A-11R-2403-07 | — | — | 0.820 |
| 10 | SRR5088837 | — | — | 0.813 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.550 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.470 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.460 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.370 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.350 | Temsirolimus | — uncovered |
| MYOGENESIS | 0.330 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.330 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.290 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.290 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.260 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.260 | Idelalisib | — uncovered |
| COAGULATION | 0.240 | Binimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.240 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.230 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.220 | Inavolisib | — uncovered |
| APOPTOSIS | 0.210 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.210 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.190 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.190 | Inavolisib | — uncovered |